Gut microbiota to be harnessed as a tool to diagnose diseases
A recent study at the University of Jyväskylä in Finland compared the gut microbiota and…
A recent study at the University of Jyväskylä in Finland compared the gut microbiota and…
There is currently no drug for treating non-alcoholic fatty liver disease, which affects many people…
Alcohol-related liver disease is among the most common causes of morbidity and mortality worldwide. Due…
Vir Biotechnology, Inc. today (November 8) announced new data from its robust hepatitis B virus…
Drug development programs will be driven forward by a collaboration between Alimentiv Inc. and Summit…
Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a…
GENFIT has entered into an exclusivity agreement with a view to acquire all the share…
Two companies set on making improvements for those with lung cancer, non-alcoholic fatty liver disease…
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharma company focused on the development of innovative therapies to…
Despite several high-profile trial failures in the field, multiple players are getting close to the…
With the close of its Series A round at €48M ($54M), the tissue models company…
Medical imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), and ultrasound have…